Abstract:Background and Objective: Non-alcoholic fatty liver disease (NAFLD) is highly prevalent in patients who undergo liver transplantation (LT). Whereas there is huge data on NAFLD, little is known about NAFLD in LT. In this review, we aim to explore extrahepatic organs and their potential mechanisms in the development of NAFLD in LT patients and discuss current limitations in preclinical and clinical scenarios with suggestions for future study. Methods: The following keywords, such as NAFLD, NASH, liver transplant, therapy, pathogenesis and biomarkers, were set for literature retrieval. The articles which were published articles in English till 25th June 2020 in PubMed database were included, and there is no limit for the study design type. Key Content and Findings: Following LT, there are significant shifts in the microbiota and farnesoid X receptor may be a potential therapeutic target for NAFLD in LT settings. The roles of probiotics and diet on NALFD remain inconclusive in LT background. Nevertheless, the adipokines and cytokines disorder and local insulin resistance of adipose tissue may contribute to NAFLD process. Bariatric surgeries are promising in controlling de novo and recurrent NAFLD with significant reduction in abdominal adipose tissue, despite the optimal timing is inconclusive in LT cases. Furthermore, circumstantial evidence indicates that miRNA33a may function as a mediator bridging sarcopenia and NAFLD of post-LT. beta-Hydroxy-beta-Methyl-Butyrate treatment could improve muscle status in graft recipients and shows protective potential for NAFLD in LT settings. Conclusions: Gut, adipose tissue and muscle are intricately intertwined in promoting NAFLD in LT cases. Further animal studies are needed to deepen our understanding of mechanisms in multi-organ crosstalk. High quality clinical trials are warrant for making guidelines and developing management strategies on NAFLD after LT.

Fecal Microbiota Transplantation for the Treatment of Nonalcoholic Fatty Liver Disease

Fecal microbiota transplantation for treatment of non-alcoholic fatty liver disease: Mechanism, clinical evidence, and prospect

Effect of Fecal Microbiota Transplantation on Non-Alcoholic Fatty Liver Disease: A Randomized Clinical Trial

Mechanisms of Nonalcoholic Fatty Liver Disease Induced by Antibiotic Resistance and Evaluation of Bacteriophag-Efficacy

Fecal Microbiota Transplantation in NAFLD Treatment

Extrahepatic Organs in the Development of Non-Alcoholic Fatty Liver Disease in Liver Transplant Patients.

Extrahepatic organs in the development of non-alcoholic fatty liver disease in liver transplant patients

Role of Bile Acids in Dysbiosis and Treatment of Nonalcoholic Fatty Liver Disease

An Update on the Efficacy and Functionality of Probiotics for the Treatment of Non-Alcoholic Fatty Liver Disease

Effect of Probiotics Therapy on Nonalcoholic Fatty Liver Disease.

Therapeutic advances in non-alcoholic fatty liver disease: A microbiota-centered view

Intestinal microbiome and NAFLD: molecular insights and therapeutic perspectives

Research Progress of Fecal Microbiota Transplantation in Liver Diseases

Allogenic Fecal Microbiota Transplantation in Patients With Nonalcoholic Fatty Liver Disease Improves Abnormal Small Intestinal Permeability: A Randomized Control Trial.

Mechanistic and physiological approaches of fecal microbiota transplantation in the management of NAFLD

Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease

The Gut Microbiota and its Metabolites, Novel Targets for Treating and Preventing Non-Alcoholic Fatty Liver Disease.

The Molecular and Mechanistic Insights Based on Gut–Liver Axis: Nutritional Target for Non-Alcoholic Fatty Liver Disease (NAFLD) Improvement

Studies in steroid metabolism; the characterization of carbonyl and other functional groups in steroids by infrared spectrometry.

Probiotics and Non-Alcoholic Fatty Liver Disease: Unveiling the Mechanisms of Lactobacillus plantarum and Bifidobacterium bifidum in Modulating Lipid Metabolism, Inflammation, and Intestinal Barrier Integrity

Herbal therapy for ameliorating nonalcoholic fatty liver disease via rebuilding the intestinal microecology